Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 20/20 | 0.58 |
| ▸ | PSEN2 | P49810 | 20/20 | 0.58 |
| ▸ | APH1B | Q8WW43 | 20/20 | 0.58 |
| ▸ | NCSTN | Q92542 | 20/20 | 0.58 |
| ▸ | APH1A | Q96BI3 | 20/20 | 0.58 |
| ▸ | PSENEN | Q9NZ42 | 20/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL139470 | 0.89 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL138871 | 0.85 | PSEN1 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL139498 | 0.80 | PSEN1 (0.60) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL139460 | 0.80 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL139606 | 0.79 | PSEN1 (0.65) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL138067 | 0.79 | PSEN1 (0.55) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL139517 | 0.77 | PSEN1 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL139605 | 0.76 | PSEN1 (0.66) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL138032 | 0.75 | PSEN1 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL138968 | 0.75 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901309-B2 | Fused triazoles for the treatment or prophylaxis of mild cognitive impairment | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8901309-B2 | Fused triazoles for the treatment or prophylaxis of mild cognitive impairment | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8901309-B2 | Fused triazoles for the treatment or prophylaxis of mild cognitive impairment | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20140350260-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-11-27 | — | — | US | disclosed |
| US-20140350260-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-11-27 | — | — | US | disclosed |
| US-8822699-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822699-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822699-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20130178497-A1 | FUSED TRIAZOLES FOR THE TREATMENT OR PROPHYLAXIS OF MILD COGNITIVE IMPAIRMENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-11 | — | — | US | disclosed |
| US-20130178497-A1 | FUSED TRIAZOLES FOR THE TREATMENT OR PROPHYLAXIS OF MILD COGNITIVE IMPAIRMENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-11 | — | — | US | disclosed |
| US-20130178497-A1 | FUSED TRIAZOLES FOR THE TREATMENT OR PROPHYLAXIS OF MILD COGNITIVE IMPAIRMENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-11 | — | — | US | disclosed |
| US-20120059030-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059030-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059030-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178497-A1 | FUSED TRIAZOLES FOR THE TREATMENT OR PROPHYLAXIS OF MILD COGNITIVE IMPAIRMENT | BACE1, BACE2, APP | PSEN1 4/4885PSEN2 5/4885APH1B 7/4885 |
| US-20120059030-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BACE1, BACE2, APP | PSEN1 5/4885PSEN2 8/4885APH1B 6/4885 |
| US-20140350260-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BACE1, BACE2, APP | PSEN1 5/4885PSEN2 8/4885APH1B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.